Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

Nelly G. Adel, PharmD, BCOP, BCPS, Elaine Duck, RN, MA, MS, Karen Collum, RN, MSN, OCN, Emily Mccullagh, NP_C, Lilian Reich, MD, Heather Landau, MD, Sergio Giralt, MD, Hani Hassoun, MD

Blood (2011) 118 (21): 4059.

https://doi.org/10.1182/blood.V118.21.4059.4059

Published: 2011

Journal Articles

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Nelly G. Adel, PharmD, Mathew Sherry, Pharm.D., Stephen J. Harnicar, PharmD, Emily Mccullagh, NP, Heather Landau, MD, Sergio Giralt, MD, Jill Vanak, Danielle Chimento, Charles Lucarelli, Matthew J. Matasar, MD, MS, Hani Hassoun, MD

Blood (2010) 116 (21): 2263.

https://doi.org/10.1182/blood.V116.21.2263.2263

Published: 2010

Journal Articles

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Heather Landau, MD, Hani Hassoun, MD, Adam D Cohen, MD, Alexander Lesokhin, MD, Christina Bello, Elizabeth Hoover, Elyn R Riedel, MD, Jennifer Ciminiello, RN, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD, Raymond Comenzo, MD

Blood (2009) 114 (22): 533.

https://doi.org/10.1182/blood.V114.22.533.533

Published: 2009

Journal Articles

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Hani Hassoun, MD, Heather Landau, MD, Chirag Surti, Nelly G. Adel, PharmD, Xiaoyu Jia, MS, Elyn R Riedel, MA, Bhutani Manisha, MD, Raymond Comenzo, MD, Alexander Lesokhin, MD, David J. Chung, MD, PhD, Jennifer Ciminiello, NP, Emily McCullagh, RN, NP-C, OCN, Stephen D Nimer, MD

Blood (2009) 114 (22): 1865.

https://doi.org/10.1182/blood.V114.22.1865.1865

Published: 2009

Journal Articles

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Trudy N. Small, MD, Robert D. Rice, RN, Emily McCullagh, Ariela Noy, Tanya Trippett, Steven M. Horwitz, Andrew D. Zelenetz, Craig Moskowitz

Blood (2007) 110 (11): 603.

https://doi.org/10.1182/blood.V110.11.603.603

Published: 2007

NARROW

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Cost Analysis of Using Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients Treated At Memorial Sloan-Kettering Cancer Center (MSKCC),

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Adjuvant Bortezomib and Dexamethasone Following Risk-Adapted Melphalan and Stem Cell Transplant in Systemic Light-Chain Amyloidosis (AL): A Phase II Study.

Outcome of Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation in the Era of Novel Therapies.

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only